Interstitial lung disease in systemic sclerosis: current and future treatment

被引：65

作者：

Giacomelli, Roberto ^{[1
]}

Liakouli, Vasiliki ^{[1
]}

Berardicurti, Onorina ^{[1
]}

Ruscitti, Piero ^{[1
]}

Di Benedetto, Paola ^{[1
]}

Carubbi, Francesco ^{[1
]}

Guggino, Giuliana ^{[2
]}

Di Bartolomeo, Salvatore ^{[1
]}

Ciccia, Francesco ^{[2
]}

Triolo, Giovanni ^{[2
]}

Cipriani, Paola ^{[1
]}

机构：

[1] Univ Aquila, Sch Med, Rheumatol Unit, Dept Biotechnol & Appl Clin Sci, Delta 6 Bldg,Via Osped, I-67100 Laquila, Italy

[2] Univ Palermo, Div Rheumatol, Dept Internal Med, Palermo, Italy

来源：

RHEUMATOLOGY INTERNATIONAL | 2017年 / 37卷 / 06期

关键词：

Systemic sclerosis; Scleroderma; Interstitial lung disease; Fibrosis; Treatment; STEM-CELL TRANSPLANTATION; PLACEBO-CONTROLLED TRIAL; ENDOTHELIN TYPE-A; PULMONARY-FIBROSIS; OPEN-LABEL; PULSE CYCLOPHOSPHAMIDE; T-CELL; BRONCHOALVEOLAR LAVAGE; MYCOPHENOLATE-MOFETIL; MOLECULAR-MECHANISMS;

D O I：

10.1007/s00296-016-3636-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Systemic sclerosis (SSc) has the highest fatality rate among connective tissue diseases and is characterized by vascular damage, inflammation and fibrosis of the skin and various internal organs. Interstitial lung disease (ILD) frequently complicates SSc and can be a debilitating disorder with a poor prognosis. ILD is the most frequent cause of death in SSc, and the management of SSc-ILD patients is a great challenge. Early detection of pulmonary involvement based on a recent decline of lung function tests and on the extent of lung involvement at high-resolution computed tomography is critical for the best management of these patients. This article summarizes classification, pathogenesis, diagnosis, prognosis, survival and finally current and future treatment options in SSc-ILD.

引用

页码：853 / 863

页数：11

共 50 条

[1] Interstitial lung disease in systemic sclerosis: current and future treatment
Roberto Giacomelli
Vasiliki Liakouli
Onorina Berardicurti
Piero Ruscitti
Paola Di Benedetto
Francesco Carubbi
Giuliana Guggino
Salvatore Di Bartolomeo
Francesco Ciccia
Giovanni Triolo
Paola Cipriani
[J]. Rheumatology International, 2017, 37 : 853 - 863
[2] Current treatment of systemic sclerosis-associated interstitial lung disease
Bes, Cemal
Cetinkaya, Erdogan
[J]. TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2022, 70 (01): : 85 - 92
[3] Interstitial lung disease in systemic sclerosis - Treatment
Hellmich, B
Schnabel, A
Bauer, T
Schatz, H
[J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2002, 127 (10) : 520 - 522
[4] Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease
Distler, Oliver
Volkmann, Elizabeth R.
Hoffmann-Vold, Anna Maria
Maher, Toby M.
[J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (10) : 1009 - 1017
[5] INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS
Abdessemed, A.
Khaldoun, N.
Brahimi, N.
Ladjouze, A.
[J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : S152 - S152
[6] Interstitial lung disease in systemic sclerosis
Ostojic, Predrag
Cerinic, Marco Matucci
Silver, Richard
Highland, Kristin
Damjanov, Nemanja
[J]. LUNG, 2007, 185 (04) : 211 - 220
[7] Interstitial lung disease in systemic sclerosis
Wells, Athol U.
[J]. PRESSE MEDICALE, 2014, 43 (10): : E329 - E343
[8] Interstitial lung disease in systemic sclerosis
Kaloudi, O.
Miniati, I.
Alari, S.
Matucci-Cerinic, M.
[J]. INTERNAL AND EMERGENCY MEDICINE, 2007, 2 (04) : 250 - 255
[9] Interstitial lung disease in systemic sclerosis
Marasini, B.
Belloli, L.
Massarotti, M.
[J]. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2007, 20 (02): : 223 - 228
[10] Interstitial Lung Disease in Systemic Sclerosis
Predrag Ostojic
Marco Matucci Cerinic
Richard Silver
Kristin Highland
Nemanja Damjanov
[J]. Lung, 2007, 185 : 211 - 220

← 1 2 3 4 5 →